212Pb-radioimmunotherapy induces G2 cell-cycle arrest and delays DNA damage repair in tumor xenografts in a model for disseminated intraperitoneal disease

Molecular Cancer Therapeutics

Volumn 11, Issue 3, 2012, Pages 639-648

  Yong, Kwon Joong ^a   Milenic, Diane E ^a   Baidoo, Kwamena E ^a   Brechbiel, Martin W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 ISOTHIOCYANATOBENZYL) 1,4,7,10 TETRAAZA 1,4,7,10 TETRA(2 CARBAMOYLMETHYL)CYCLODODECANE; BISMUTH 212; BISMUTH 213; BROXURIDINE; DODECANE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOGLOBULIN G; LEAD 212; PROTEIN P21; RAD51 PROTEIN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ALPHA RADIATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL KILLING; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN STRUCTURE; COLON CANCER; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DNA SYNTHESIS; DOUBLE STRANDED DNA BREAK; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOIMMUNOTHERAPY; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; FEMALE; FLOW CYTOMETRY; G2 PHASE; HETEROCYCLIC COMPOUNDS; HUMANS; IMMUNOGLOBULIN G; ISOTHIOCYANATES; LEAD RADIOISOTOPES; MICE; MICE, NUDE; PERITONEAL NEOPLASMS; RADIOIMMUNOTHERAPY; TIME FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84859386203     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0671     Document Type: Article

References (48)

1. Park SI, Press OW. Radioimmunotherapy for treatment of B-cell lymphomas and other hematologic malignancies. Curr Opin Hematol 2007;14:632-8. (Pubitemid 47494079)
2. DeNardo GL, DeNardo SJ, Balhorn R. Systemic radiotherapy can cure lymphoma: a paradigm for other malignancies? Cancer Biother Radiopharm 2008;23:383-97.
3. Zhang M, Yao Z, Garmestani K, Axworthy DB, Zhang Z, Mallett RW, et al. Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the α-emitting radionuclide, bismuth 213. Blood 2002;100:208-16. (Pubitemid 35177449)
4. Zhang M, Zhang Z, Garmestani K, Schultz J, Axworthy DB, Goldman CK, et al. Pre-target radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts. Proc Natl Acad Sci U S A 2003;100:1891-5. (Pubitemid 36254544)
5. 212Bi linked to an anti-pancreatic carcinoma antibody: Model for α-particle-emitter radioimmunotherapy. J Natl Cancer Inst 1988;80:449-52.
6. Milenic DE, Garmestani K, Brady ED, Albert PS, Ma D, Abdulla A, et al. Targeting of HER2 antigen for the treatment of disseminated peritoneal disease. Clin Cancer Res 2004;10:7834-41. (Pubitemid 39587521)
7. Milenic DE, Brechbiel MW. Targeting of radioisotopes for cancer therapy. Cancer Biol Ther 2004;3:361-70.
8. 212Pb-labeled radioimmunoconjugate targeting HER2. Cancer Biother Radiopharm 2005;20:557-68.
9. Su FM, Beaumier P, Axworthy D, Atcher R, Fritzberg A. Pre-targeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator. Nucl Med Biol 2005;32:741-7. (Pubitemid 41502980)
10. Roger M, Macklis MD, William D, Kaplan MD, James LM, Ferrara MD, et al. Resident's essay award: alpha particle radio-immunotherapy: animal models and clinical prospects. Int J Radiat Oncol Biol Phys 1989;16:1377-87.
11. 212Pb as a clinical therapeutic; getting the lead in! Dalton Trans 2011;40:6068-76.
12. Baselga J. Phase I and II clinical trials of trastuzumab. Ann Oncol 2001;12:49-55.
13. Aqus DB, Bunn PA Jr, Franklin W, Garcia M, Ozols RF. Her-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer. Semin Oncol 2000;27:53-63. (Pubitemid 32172257)
14. Chappell LL, Dadachova E, Milenic DE, Garmestani K, Wu C, Brechbiel MW. Synthesis, characterization, and evaluation of a novel bifunctional chelating agent for the lead isotopes 203Pb and 212Pb. Nucl Med Biol 2000;27:93-100. (Pubitemid 30099621)
15. Nunez MI, Villalobos M, Olea N, Valenzuela MT, Pedraza V, McMillan TJ, et al. Radiation-induced DNA double-strand breaks rejoining in human tumor cells. Br J Cancer 1995;71:311-6.
16. Kolesnick RN, Haimovitz-Friedman A, Fuks Z. The sphingomyelin signal transduction pathway mediates apoptosis for tumor necrosis factor, Fas, and ionizing radiation. Biochem Cell Biol 1994;72: 471-4.
17. Pandita TK, Lieberman HB, Lim DS, Dhar S, Zheng W, Taya Y, et al. Ionizing radiation activates the ATM kinase throughout the cell cycle. Oncogene 2000;19:1386-91. (Pubitemid 30171169)
18. Munro TR. The relative radiosensitivity of the nucleus and cytoplasm of Chinese hamster fibroblasts. Radiat Res 1970;42:451-70.
19. Søyland C, Hassfjell SP. Survival of human lung epithelial cells following in vitro α-particle irradiation with absolute determination of the number of alpha-particle traversals of individual cells. Int J Radiat Biol 2000;76:1315-22.
20. Seidl C, Schrock H, Seidenschwang S, Beck R, Schmid E, Abend M, et al. Cell death triggered by alpha-emitting 213Bi-immunoconjugates in HSC-M2 gastric cancer cells is different from apoptotic cell death. Eur J Nucl Med Mol Imaging 2005;32:274-85. (Pubitemid 40562118)
21. 213Bi anti-CD45 antibodies in Leukemia cells. Cancer Res 2007;67:1950-8.
22. Supiot S, Gouard S, Charrier J, Apostolidis C, Chatal JF, Barbet J, et al. Mechanisms of cell sensitization to α-radioimmunotherapy by doxorubicin or paclitaxel in multiple myeloma cell lines. Clin Cancer Res 2005;11:7047-52.
23. Tom BH, Rutzky LP, Jakstys MM, Oyasu R, Kaye CI, Kahan BD. Human colonic adenocarcinoma cells. I. Establishment and description of a new cell line. In Vitro 1976;12:180-91.
24. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951;193:265-75.
25. Dadachova E, Chappell LL, Brechbiel MW. Spectrophotometric method for determination of bifunctional macrocyclic ligands in macrocyclic ligand-protein conjugates. Nucl Med Biol 1999;26:977-82. (Pubitemid 30047170)
26. Milenic DE, Wong KJ, Baidoo KE, Nayak TK, Regino CA, Garmestani K, et al. Targeting HER2: a report on the in vitro and in vivo pre-clinical data supporting trastuzumab as a radioimmunoconjugate for clinical trials. MAbs 2010;2:550-64.
27. Grégoire V, Van NT, Stephens LC, Brock WA, Milas L, Plunkett W, et al. The role of fludarabine-induced apoptosis and cell cycle synchronization in enhanced murine tumor radiation response in vivo. Cancer Res 1994;54:6201-9. (Pubitemid 24378654)
28. Stephens LC, Ang KK, Schultheiss TE, Milas L, Meyn RE. Apoptosis in irradiated murine tumors. Radiat Res 1991;127:308-16.
29. Kaufmann SH, Earnshaw WC. Introduction of apoptosis by cancer therapy. Exp Cell Res 2000;256:42-9.
30. Hengartner MO. The biochemistry of apoptosis. Nature 2000;407: 770-6.
31. Leonard CE, Chan DC, Chou TC, Kumar R, Bunn PA. Paclitaxel enhances in vitro radiosensitivity of squamous carcinoma cell lines of the head and neck. Cancer Res 1996;56:5198-204. (Pubitemid 26383036)
32. Helleday T, Lo J, van Gent DC, Engelward BP. DNA double-strand break repair: from mechanistic understanding to cancer treatment. DNA Repair 2007;6:923-35. (Pubitemid 46880473)
33. Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor-2 positive breast cancer. J Clin Oncol 2009;27:5838-47.
34. Podhorecka M, Skladanowski A, Bozko P. H2AX phosphorylation: its role in DNA damage response and cancer therapy. J Nucleic Acids 2010;2010:1-9.
35. Jenuwein T, Allis CD. Translating the histone code. Science 2001;293: 1074-80. (Pubitemid 32758077)
36. Kondo Y, Issa JP. Enrichment for histone H3 lysine 9 methylation at Alu repeats in human cells. J Biol Chem 2003;278:27658-62. (Pubitemid 36899953)
37. Kondo Y, Shen L, Issa JP. Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer. Mol Cell Biol 2003; 23:206-15. (Pubitemid 36008514)
38. Liang K, Lu Y, Jin W, Ang KK, Milas L, Fan Z. Sensitization of breast cancer cells to radiation by trastuzumab. Mol Cancer Ther 2003;2: 1113-20.
39. Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ. Antibody to Her2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994;9: 1829-38. (Pubitemid 24194147)
40. Ko JC, Hong JH, Wang LH, Cheng CM, Ciou SC, Lin ST, et al. Role of repair protein Rad51 in regulating the response to gefitinib in human non-small cell lung cancer cells. Mol Cancer Ther 2008;7: 3632-41.
41. West SC. Molecular views of recombination proteins and their control. Nat Rev Mol Cell Biol 2003;4:435-45. (Pubitemid 36648589)
42. 213Bi-C-functionized transcyclohexyl- diethylenetriaminepentaacetic acid-humanized 3S193 is enhanced by combination with paclitaxel chemotherapy. Clin Cancer Res 2007;13:5604-12.
43. 213Bi-Herceptin alpha conjugate. Cancer Lett 2004; 205:161-71.
44. Macklis RM, Lin JY, Beresford B, Atcher RW, Hines JJ, Humm JL. Cellular kinetics, dosimetry, and radiobiology of α-particle radioimmunotherapy: Induction of apoptosis. Radiat Res 1992;130: 220-6.
45. Pouget JP, Mather SJ. General aspects of the cellular response to low- and high-LET radiation. Eur J Nucl Med 2001;28: 541-61. (Pubitemid 32260923)
46. Abend M. Reasons to reconsider the significance of apoptosis for cancer therapy. Int J Radiat Biol 2003;79:927-41. (Pubitemid 38147054)
47. Sinclair WK, Morton RA. X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells. Radiat Res 1966;29: 450-74.
48. Wendt J, Radetzki S, von Haefen C, Hemmati PG, Guner D, Schulze-Osthoff K, et al. Induction of p21CIP/WAF-1 and G2 arrest by ionizing irradiation impedes caspase-3-mediated apoptosis in human carcinoma cells. Oncogene 2006;25:972-80. (Pubitemid 43277005)